

WEST**Freeform Search****Database:**

US Patents Full-Text Database
US Pre-Grant Publication Full-Text Database
JPO Abstracts Database
EPO Abstracts Database
Derwent World Patents Index
IBM Technical Disclosure Bulletins

Term:

liposome near6 lipase

Display:

20

Documents in Display Format:

-

Starting with Number

1

Generate: ☐ Hit List ☒ Hit Count ☐ Side by Side ☐ Image

Search

Clear

Help

Logout

Interrupt

Main Menu

Show S Numbers

Edit S Numbers

Preferences

Cases

Search History**DATE:** Wednesday, July 23, 2003 [Printable Copy](#) [Create Case](#)**Set Name Query**

side by side

*DB=USPT,PGPB; PLUR=YES; OP=AND***Hit Count Set Name**

result set

L3 liposome near6 lipase26 L3L2 liposome near7 cpat near5 (n-terminal or c-terminal or fragment or component)0 L2L1 liposome near7 lipase near5 (n-terminal or c-terminal or fragment or component)2 L1

END OF SEARCH HISTORY

[Generate Collection](#)[Print](#)**Search Results - Record(s) 1 through 2 of 2 returned.**

☐ 1. [20020035084](#). 21 Nov 01. 21 Mar 02. Pharmaceuticals and assays using enzyme subunits. Titball, Richard W., et al. 514/44; 424/146.1 A61K048/00 A61K039/395.

☐ 2. [6472365](#). 16 Mar 98; 29 Oct 02. Pharmaceuticals and assays using enzyme subunits. Titball; Richard W, et al. 514/1; 424/130.1 424/134.1 424/141.1 424/152.1 514/2. A01N061/00 A01N037/18 A61K039/395.

[Generate Collection](#)[Print](#)

Terms	Documents
liposome near7 lipase near5 (n-terminal or c-terminal or fragment or component)	2

[Previous Page](#)[Next Page](#)

[Generate Collection](#)[Print](#)**Search Results - Record(s) 1 through 20 of 26 returned.**

-
- ☐ 1. [20030059420](#) . 02 Feb 01. 27 Mar 03. Lipid hydrolysis therapy for atherosclerosis and related diseases. Grabowski, Gregory, et al. 424/94.6; 514/8 A61K038/46 A61K038/16.
-
- ☐ 2. [20020035084](#) . 21 Nov 01. 21 Mar 02. Pharmaceuticals and assays using enzyme subunits. Titball, Richard W., et al. 514/44; 424/146.1 A61K048/00 A61K039/395.
-
- ☐ 3. [20020012651](#) . 10 May 01. 31 Jan 02. Release of therapeutic agents in a vessel or tissue. Loeb, Marvin P.. 424/85.1; 424/130.1 424/450 424/94.1 514/44 A61K048/00 A61K038/19 A61K039/395 A61K038/43 A61K009/127.
-
- ☐ 4. [20020001614](#) . 09 Feb 01. 03 Jan 02. Lipid-based drug delivery systems containing phospholipase A2 degradable lipid derivatives and the therapeutic uses thereof. Jorgensen, Kent, et al. 424/450; 554/103 554/51 554/84 A61K009/127 C11C003/00.
-
- ☐ 5. [20010006950](#) . 10 Feb 99. 05 Jul 01. GENETIC VACCINE VECTOR ENGINEERING. PUNNONEN, JUHA, et al. 514/44; 435/320.1 A61K048/00.
-
- ☐ 6. [6479258](#) . 31 Jan 00; 12 Nov 02. Non-stochastic generation of genetic vaccines. Short; Jay M.. 435/69.1; 530/350 536/23.2. C12P021/06 C07K001/00 C07H021/04.
-
- ☐ 7. [6476243](#) . 27 Sep 00; 05 Nov 02. Perfluorinated esters of alkanoyl L-carnitine for the preparation of cationic lipids for the intracellular delivery of pharmacologically active compounds. Santaniello; Mose, et al. 554/121; 554/123 554/225 554/231 560/170 560/172. C07F003/06.
-
- ☐ 8. [6472365](#) . 16 Mar 98; 29 Oct 02. Pharmaceuticals and assays using enzyme subunits. Titball; Richard W, et al. 514/1; 424/130.1 424/134.1 424/141.1 424/152.1 514/2. A01N061/00 A01N037/18 A61K039/395.
-
- ☐ 9. [6379699](#) . 28 Sep 99; 30 Apr 02. Liposome having attached target-binding moiety and artherosclerotic plaque interacting moiety. Virtanen; Jorma, et al. 424/450; 424/159.1 424/160.1 424/161.1 424/178.1 424/179.1 424/193.1 424/194.1 424/94.1 424/94.2 424/94.6 424/94.61 424/94.63 435/174 435/177 435/235.1 436/528 514/44 530/812. A61K009/127 A61K038/43 A61K038/51 A61K039/395 C12N011/02.
-
- ☐ 10. [6296870](#) . 03 Feb 98; 02 Oct 01. Liposomes containing active agents. Needham; David, et al. 424/450; 424/1.21 424/9.321 424/9.51 424/94.3. A61K009/127 A61K009/133.
-
- ☐ 11. [6258528](#) . 22 Feb 99; 10 Jul 01. Signal amplification method. Carr; Frank. 435/5; 435/7.1 436/516 436/536 436/829. C12Q001/70 G01N033/53 G01N033/561 G01N033/542.
-
- ☐ 12. [6143321](#) . 19 Oct 98; 07 Nov 00. Liposomes containing active agents. Needham; David, et al. 424/450; 424/1.21 424/9.321 424/9.51 424/94.3. A61K009/127 A61K009/133.
-
- ☐ 13. [5882679](#) . 05 Aug 98; 16 Mar 99. Liposomes containing active agents aggregated with lipid surfactants. Needham; David. 424/450; A61K009/127.

-
- ☐ 14. 5876747. 08 Jul 92; 02 Mar 99. Liposome preferentially traveling to cardiac and skeletal muscles. Stracher; Alfred, et al. 424/450; 514/78 514/821 554/79 554/80. A61K009/127 A61K031/685.
-
- ☐ 15. 5827533. 06 Feb 97; 27 Oct 98. Liposomes containing active agents aggregated with lipid surfactants. Needham; David. 424/450; 424/1.21 424/9.32 424/9.51. A61K009/133 A61K009/127.
-
- ☐ 16. 5766600. 03 May 95; 16 Jun 98. Non-azo naphtalimide dyes and uses for same. Lewis; David E., et al. 424/204.1; 424/234.1 514/296. A61K039/02 A61K039/12.
-
- ☐ 17. 5665379. 13 May 94; 09 Sep 97. Lipid particle forming matrix, preparation and use thereof. Herslof; Bengt, et al. 426/450; 264/4.1 264/4.3 424/484 424/489 424/490 424/498 424/502 428/402.2. A61K009/127 A61K009/14.
-
- ☐ 18. 5626869. 29 Jun 95; 06 May 97. Pharmaceutical composition containing a defined lipid system. Nyqvist; H.ang.kan, et al. 424/450; 264/4.1 424/489 428/402.2. A61K009/127 A61K009/16.
-
- ☐ 19. 5565551. 03 May 95; 15 Oct 96. Non-azo naphthalimide dyes and uses for same. Lewis; David E., et al. 530/405; 530/402 530/403 530/409. C07K001/00 C07K014/00 C07K016/00 C07K017/00 C08H001/00.
-
- ☐ 20. 5420136. 09 Aug 93; 30 May 95. Eradication of pathogenic biological contaminants using non-azo naphthalimide dyes. Lewis; David E., et al. 514/296; 424/1.17 424/1.33 424/1.49 424/1.65 424/1.81 514/284 514/885 540/467 546/100 546/13 546/14 546/22 546/23 546/76 546/77 546/88 546/97 546/98. A61K031/435 A61K031/535 A61K031/54 A61K039/00.
-

[Generate Collection](#)[Print](#)

Terms	Documents
liposome near6 lipase	26

[Previous Page](#)[Next Page](#)

[Generate Collection](#)[Print](#)**Search Results - Record(s) 21 through 26 of 26 returned.**

-
- ☐ 21. 5235045. 19 Mar 92; 10 Aug 93. Non-azo naphthalimide dyes. Lewis; David E., et al. 534/560; 530/350 536/1.11 536/123.1 536/22.1 544/333 546/100 546/13 546/14 546/22 546/23 546/97 546/98 546/99. C07D221/18 C07D221/14 A61K031/435.
-
- ☐ 22. 5149642. 20 Apr 90; 22 Sep 92. Process for preparing 2-acylglycerides or 1,2 or 2,3-diacylglycerides. Mazur; Adam W., et al. 435/135; 435/134 435/198. C12P007/64 C12P007/62 C12N009/20.
-
- ☐ 23. 5116745. 19 Apr 90; 26 May 92. Process for preparing 2-acylglycerides or 1,2-diacyl diglycerides or 2,3-diacyl diglycerides. Mazur; Adam W., et al. 435/134; 435/198. C12P007/64 C12P007/62 C12N009/20.
-
- ☐ 24. 5008288. 04 May 89; 16 Apr 91. Carnitine directed pharmaceutical agents. Stracher; Alfred, et al. 514/535; 424/450 428/402.2 514/17 514/2 514/305 514/547 514/556 514/821 530/330 530/812. A61K031/24 A61K031/44 A61K037/02 C07K017/02.
-
- ☐ 25. 4866040. 15 Jan 87; 12 Sep 89. Aminocarnitine directed pharmaceutical agents. Stracher; Alfred, et al. 514/17; 424/450 428/402.2 514/2 514/305 514/535 514/547 514/556 514/78 514/821 530/330 930/10 930/250 930/30. A61K031/225 A61K037/02 A61K037/64 C08G069/08.
-
- ☒ 26. 4463090. 30 Sep 81; 31 Jul 84. Cascade amplification enzyme immunoassay. Harris; Curtis C.. 435/7.7; 435/13 435/188 435/23 435/24 435/7.71 435/7.9 435/7.91 435/810 435/966 435/975 436/829. G01N033/54 C12Q001/56 C12Q001/38 C12N009/96.
-

[Generate Collection](#)[Print](#)

Terms	Documents
liposome near6 lipase	26

[Previous Page](#)[Next Page](#)

=> d his

(FILE 'HOME' ENTERED AT 15:50:39 ON 23 JUL 2003)

FILE 'MEDLINE, CAPLUS, BIOSIS, SCISEARCH' ENTERED AT 15:50:58 ON 23 JUL 2003

L1 1739 S LIPOSOME(5A) (N-TERMINAL OR C-TERMINAL OR FRAGMENT OR COMPONENT
L2 34 S L1(5A) (THERAPEUTIC? OR PHARMACEUTIC? OR TK OR CYTOKINE OR GROWTH
L3 32 DUP REM L2 (2 DUPLICATES REMOVED)
L4 684 S ANTIBOD?(5A) LIPASE
L5 0 S L4 AND LIPOSOME
L6 2 S L4 AND LIPOSOME
L7 2 DUP REM L6 (0 DUPLICATES REMOVED)

=> d bib ab 1-2 17

L7 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2003 ACS on STN
AN 2000:706946 CAPLUS
DN 133:301116
TI Compositions and methods for regulating levels of high-density lipoprotein
(HDL) cholesterol and apolipoprotein A-I, very-low-density lipoprotein
(VLDL) cholesterol, and low-density lipoprotein (LDL) cholesterol
IN Jaye, Michael; Lynch, Kevin J.; Amin, Dilip V.; Doan, Kim-anh Thi;
Marchadier, Dawn; Maugeais, Cyrille; Rader, Daniel J.; Krawiec, John A.;
South, Victoria J.
PA Aventis Pharmaceuticals Products Inc., USA; The Trustees of the University
of Pennsylvania; et al.
SO PCT Int. Appl., 171 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2000057837	A2	20001005	WO 2000-US7870	20000324
	WO 2000057837	A3	20010125		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	RW:	GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
	AU 2000039187	A5	20001016	AU 2000-39187	20000324
	BR 2000009333	A	20020108	BR 2000-9333	20000324
	EP 1171078	A2	20020116	EP 2000-918362	20000324
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO			
	JP 2002540127	T2	20021126	JP 2000-607588	20000324
	NO 2001004657	A	20011121	NO 2001-4657	20010925
PRAI	US 1999-277401	A2	19990326		
	WO 2000-US7870	W	20000324		

AB Compns. and methods are disclosed for raising the level of HDL cholesterol and apolipoprotein A-I in a patient and for lowering the levels of VLDL cholesterol and LDL cholesterol in a patient, including compns. and methods which affect the expression of a gene, LIPG, which encodes a lipase that is a member of the triacylglycerol lipase family or which affect the activity of the enzyme.

L7 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1999:64709 CAPLUS
DN 130:138298

TI Decreased fat absorption with an anti-lipase antibody
 IN Pimentel, Julio L.
 PA Ximed Group Plc, UK
 SO PCT Int. Appl., 18 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9902187	A1	19990121	WO 1998-GB1998	19980706
	W:			AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM	
	RW:			GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG	
	AU 9882326	A1	19990208	AU 1998-82326	19980706
	EP 1001809	A1	20000524	EP 1998-932392	19980706
	R:			AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, NL, SE, PT, IE, FI	
	BR 9815504	A	20001128	BR 1998-15504	19980706
	JP 2001525314	T2	20011211	JP 2000-501777	19980706
	NO 2000000052	A	20000302	NO 2000-52	20000106
	BG 104061	A	20001130	BG 2000-104061	20000106
PRAI	US 1997-888202	A	19970707		
	US 1997-882202	A	19970707		
	WO 1998-GB1998	W	19980706		

AB A method for the decrease of fat absorption in any animal, wherein the animal is fed an **antibody** produced against **lipase**, an enzyme which is required for fat absorption. Avian egg-derived anti-**lipase antibodies** are disclosed for treating obesity in a mammal or an avian. Also, avian egg-derived antibodies (IgYs) against gastrointestinal enzyme such as amylase, trypsin, chymotrypsin, protease and other enzyme or antigen are used for reducing absorption of nutrients such as proteins, carbohydrates and lipids. These antibodies are mixed in food (concd., additive-added, refrigerated or frozen food) for human or animal consumption.

=>

=> d his

(FILE 'HOME' ENTERED AT 15:50:39 ON 23 JUL 2003)

FILE 'MEDLINE, CAPLUS, BIOSIS, SCISEARCH' ENTERED AT 15:50:58 ON 23 JUL 2003

L1 1739 S LIPOSOME(5A) (N-TERMINAL OR C-TERMINAL OR FRAGMENT OR COMPONENT
L2 34 S L1(5A) (THERAPEUTIC? OR PHARMACEUTIC? OR TK OR CYTOKINE OR GRO
L3 32 DUP REM L2 (2 DUPLICATES REMOVED)
L4 684 S ANTIBOD?(5A)LIPASE
L5 0 S L4 AND LIPOSOME
L6 2 S L4 AND LIPOSOME
L7 2 DUP REM L6 (0 DUPLICATES REMOVED)
L8 875 S ANTIBOD?(8A)LIPASE
L9 2 S L8 AND LIPOSOME
L10 7532 S LIPOSOME(5A) (THERAPEUTIC? OR PHARMACEUTIC? OR TK OR CYTOKINE
L11 1033 S LIPASE(5A) (N-TERMINAL OR C-TERMINAL OR FRAGMENT OR COMPONENT)
L12 0 S L10 AND L11
L13 7 S L11 AND LIPOSOME
L14 7 DUP REM L13 (0 DUPLICATES REMOVED)

=> d bib ab 1-7 l14

L14 ANSWER 1 OF 7 CAPLUS COPYRIGHT 2003 ACS on STN
AN 2001:208507 CAPLUS
DN 134:234000
TI Spatially-addressed lipid bilayer arrays and lipid bilayers with
addressable confined aqueous compartments
IN Cremer, Paul S.; Simanek, Eric E.; Yang, Tinglu
PA The Texas A & M University System, USA
SO PCT Int. Appl., 87 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001020330	A1	20010322	WO 2000-US25627	20000918
	W:				
					AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
	RW:				GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
	EP 1218745	A1	20020703	EP 2000-963609	20000918
	R:				AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL

PRAI US 1999-154576P P 19990917
US 2000-564708 A 20000504
WO 2000-US25627 W 20000918

AB Disclosed are spatially-addressed arrays of discreet fluid lipid bilayers prepd. by flexible patterning methods that facilitate the compartmentalization of lipid membranes and aq. solns. disposed thereon into discreet, spatially-addressable, microarray partitions, onto specific and discreet locations of a substantially planar solid support. This process can either be used in parallel or sequentially to pattern thousands of distinct membranes on a single "biochip", and to assay pluralities of selected analyte components contacted with the discreet lipid bilayer compartments for one or more target mols. Also provided are biochip microarray systems and methods for their prodn. that comprise arrays of confined aq. compartments disposed upon such compartmentalized

lipid bilayers. The aq. compartments are independently addressable, thereby facilitating reagent delivery, reagent extn., anal. probe and high-throughput analyte screening methods.

RE.CNT 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L14 ANSWER 2 OF 7 CAPLUS COPYRIGHT 2003 ACS on STN

AN 1998:668010 CAPLUS

DN 129:306499

TI BAL C-tail drug delivery molecules

IN Tang, Jordan J. N.; Wang, Chi-Sun

PA Oklahoma Medical Research Foundation, USA

SO U.S., 16 pp., Cont.-in-part of U.S. 5,696,087.

CODEN: USXXAM

DT Patent

LA English

FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 5821226	A	19981013	US 1995-482262	19950607
	US 5696087	A	19971209	US 1994-347718	19941201
	CA 2206526	AA	19960606	CA 1995-2206526	19951201
	WO 9617054	A1	19960606	WO 1995-US15647	19951201
	W: AU, CA, JP				
	RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
	AU 9645064	A1	19960619	AU 1996-45064	19951201
	AU 707558	B2	19990715		
	EP 795011	A1	19970917	EP 1995-943643	19951201
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
	JP 3007161	B2	20000207	JP 1996-519095	19951201
	JP 10510166	T2	19981006		
PRAI	US 1994-347718	A2	19941201		
	US 1995-479160	A	19950607		
	US 1995-482262	A	19950607		
	WO 1995-US15647	W	19951201		

AB Drug delivery conjugates of a BAL C-tail peptide, including all or a portion of the carboxy terminal region of human bile salt-activated lipase (BAL), conjugated to a biol. active substance are described. The C-tail peptide-drug conjugates, when orally ingested, compete with native BAL in binding to the intestinal surface, and, as a result, permit drug compns. to be delivered specifically to the intestine. Useful C-tail peptides are derivs. of the carboxy terminal region of BAL derived from all or portion of the region contg. amino acid residues 539 to 722, and have a mucin-like structure contg. at least three of the repeating proline-rich units of eleven amino acid residues each.

RE.CNT 78 THERE ARE 78 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L14 ANSWER 3 OF 7 CAPLUS COPYRIGHT 2003 ACS on STN

AN 1996:446972 CAPLUS

DN 125:96049

TI Method and compositions containing human bile salt **lipase fragment** for reducing intestinal absorption of cholesterol

IN Tang, Jordan J. N.; Wang, Chi-Sun

PA Oklahoma Medical Research Foundation, USA

SO PCT Int. Appl., 99 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9617054	A1	19960606	WO 1995-US15647	19951201
	W: AU, CA, JP				

RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE

US 5696087	A	19971209	US 1994-347718	19941201
US 5681819	A	19971028	US 1995-479160	19950607
US 5821226	A	19981013	US 1995-482262	19950607
AU 9645064	A1	19960619	AU 1996-45064	19951201
AU 707558	B2	19990715		
EP 795011	A1	19970917	EP 1995-943643	19951201

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE

JP 3007161	B2	20000207	JP 1996-519095	19951201
JP 10510166	T2	19981006		

PRAI US 1994-347718 A 19941201

US 1995-479160	A	19950607
US 1995-482262	A	19950607
WO 1995-US15647	W	19951201

AB Compns. derived from all or a portion of the carboxy terminal region of human bile salt-activated lipase (BAL) are described, which, when orally ingested, compete with native BAL in binding to the intestinal surface, thus reducing the physiol. role of BAL in mediating the transfer of cholesterol into the intestinal cells, and, as a result, reducing the amt. of cholesterol absorbed from the intestine into the blood stream. Useful derivs. of the carboxy terminal region of BAL are derived from all or portion of the region contg. amino acid residues 539 to 722, and have a mucin-like structure contg. at least three of the repeating proline-rich units of eleven amino acid residues each. Conjugates of the BAL peptide and biol. active substances (such as proteins, vitamins, chemotherapeutic agents, etc.) are also claimed. The C-terminus of BAL was found to be involved in binding of BAL to intestinal epithelial lining cells. Addn. of the C-terminal fragment to intestinal content released bound endogenous BAL. This fragment competitively inhibited cholesterol uptake in the rat intestine. BAL was shown to mediate uptake of triglycerides but not taurocholate in isolated rat intestinal tissue.

L14 ANSWER 4 OF 7 CAPLUS COPYRIGHT 2003 ACS on STN

AN 1986:586483 CAPLUS

DN 105:186483

TI Activation of lipoprotein lipase by N-.alpha.-palmitoyl (56-79) fragment of apolipoprotein C-II

AU Balasubramaniam, Ambikaipakan; Rechten, Ann; Mclean, Larry R.; Jackson, Richard L.; Demel, Rudy A.

CS Merrell Dow Res. Inst., Cincinnati, OH, USA

SO Biochemical and Biophysical Research Communications (1986), 137(3), 1041-8

CODEN: BBRCA9; ISSN: 0006-291X

DT Journal

LA English

AB The effect of apolipoprotein C-II (apoC-II) and a synthetic fragment of apoC-II corresponding to residues 56-79 on the lipoprotein lipase (LpL)-catalyzed hydrolysis of trioleoylglycerol in a monolayer of egg phosphatidylcholine and of dipalmitoylphosphatidylcholine vesicles was examd. Synthetic peptide 56-79, which does not assoc. with lipid, did not activate LpL at surface pressures >30 mN/m; apoC-II is active at .ltoreq.34 mN/m. However, acylation of the N-terminus of peptide 56-79 with palmitoyl chloride gave nearly identical LpL-activating properties as compared to apoC-II. Thus, at high surface pressures, the lipid-binding region of apoC-II (residues 44-55) plays an essential role in LpL activation.

L14 ANSWER 5 OF 7 CAPLUS COPYRIGHT 2003 ACS on STN

AN 1982:176780 CAPLUS

DN 96:176780

TI Lipoprotein lipase interaction with synthetic N-dansyl fragments of apolipoprotein C-II

AU Smith, Louis C.; Voyta, John C.; Kinnunen, Paavo K. J.; Gotto, Antonio M., Jr.; Sparrow, James T.

CS Baylor Coll. Med., Houston, TX, 77030, USA

SO Biophysical Journal (1982), 37(1), 174-5
 CODEN: BIOJAU; ISSN: 0006-3495

DT Journal

LA English

AB The activation of bovine milk lipoprotein **lipase** by synthetic **fragments** of apolipoprotein C-II (apoC-II) contg. a single dansyl group (DNS) on the N-terminal residue [(apoC-II-DNS-(64-78), apoC-II-DNS-(60-78), apoC-II-DNS-(55-78), apoC-II-DNS-(50-78), and apoC-II-DNS-(43-78)] was 0, 60, 80, 90, and 100%, resp., of that produced by native apoC-II. The corresponding resp. assocn. consts. were 0.25, 1.25, 4.6, 0.5, and 2.0 .times. 106 M-1. The activation of lipoprotein lipase was detd. in the absence of a substrate. Energy transfer from apoC-II-DNS-(55-78) was abolished by guanidinium chloride. Energy transfer also occurred from the enzyme in the presence of a nonhydrolyzable substrate, single-walled vesicles of 1-oleyl-2-palmityl-2-phosphorylcholine glyceryl ether. Apparently, the enhancement of lipoprotein lipase is primarily due to direct protein-protein interactions involving residues 55-74 rather than to an effect of apoC-II on the substrate surface.

L14 ANSWER 6 OF 7 CAPLUS COPYRIGHT 2003 ACS on STN

AN 1982:487714 CAPLUS

DN 97:87714

TI Immunological studies on bovine milk lipoprotein **lipase**.
 Effects of Fab **fragments** on enzyme activity

AU Shirai, Kohji; Wisner, Daniel A.; Johnson, J. David; Srivastava, Laxmi S.; Jackson, Richard L.

CS Coll. Med., Univ. Cincinnati, Cincinnati, OH, 45267, USA

SO Biochimica et Biophysica Acta (1982), 712(1), 10-20
 CODEN: BBACAQ; ISSN: 0006-3002

DT Journal

LA English

AB Rabbit antiserum against purified bovine milk lipoprotein lipase (I) was prepd. Immuno-electrophoresis of I gave a single precipitin line against the antibody; the line was coincident with enzyme activity. The .gamma.-globulin fraction inhibited heparin-releasable I activity of bovine arterial intima, heart, muscle, and adipose tissue. The antibody also inhibited the I activities of adipose tissue of human and pig, but not those of rat and dog. Fab fragments were prepd. by papain digestion of the .gamma.-globulin fraction. Fab fragments inhibited the I-catalyzed hydrolysis of dimyristoylphosphatidylcholine vesicles and triolein emulsions to the same extent. The Fab fragments also inhibited the lipolysis of human plasma very-low-d. lipoproteins. The change in the kinetic parameters for the I-catalyzed hydrolysis of triolein by the Fab fragments was accompanied by a 3-fold increase in Km and a 10-fold decrease in Vmax. Preincubation of I with apolipoprotein C-II, the activator protein for I, did not prevent inhibition of enzyme activity by the Fab fragments. However, preincubation with dipalmitoylphosphatidylcholine-emulsified triolein or Triton X-100-emulsified triolein had a protective effect (remaining activity 7.0 or 25.8%, resp., compared with 1.0 or 0.4% with no preincubation). The addn. of both apolipoprotein G-II and substrate prior to the incubation with the Fab fragments was assocd. with an increased protective effect against inhibition of enzyme activity; remaining activity with dipalmitoylphosphatidylcholine-emulsified triolein was 40.6% and with Triton X-100-emulsified triolein, 45.4%. Human plasma very-low-d. lipoproteins also protected against the inhibition of I activity by the Fab fragments. Apparently, the interaction of I with apolipoprotein C-II in the presence of lipids is assocd. with a conformational change in the structure of the enzyme such that the Fab fragments are less inhibitory. The consequence of a conformational change in I may be to facilitate the formation of an enzyme-triacylglycerol complex so as to enhance the rate of the I-catalyzed turnover of substrate to products.

L14 ANSWER 7 OF 7 CAPLUS COPYRIGHT 2003 ACS on STN

AN 1982:30689 CAPLUS

DN 96:30689

TI Limited trypsinolysis of porcine and equine colipases. Spectroscopic and kinetic studies

AU Rathelot, J.; Canioni, P.; Bosc-Bierne, I.; Sarda, L.; Kamoun, A.; Kaptein, R.; Cozzzone, P. J.

CS Lab. Biochim., Fac. St-Charles, Marseille, 13003, Fr.

SO Biochimica et Biophysica Acta (1981), 671(2), 155-63

CODEN: BBACAQ; ISSN: 0006-3002

DT Journal

LA English

AB On mild tryptic hydrolysis of porcine and equine colipases, proteolysis occurred at the arginine⁵-glycine⁶ bond with the loss of the N-terminal pentapeptide. Studies of native and trypsin-treated colipases by CD and laser chem. induced dynamic nuclear polarization indicate that proteolysis induces conformational changes in the region of the tyrosine cluster. Expts. in the presence of phospholipid indicate that these residues are in or close to the region of the protein interacting with aggregated lipids. Kinetic studies of the reaction of bile salt-inhibited lipase with emulsified triolein in the absence and in the presence of lecithin show that tryptic hydrolysis of the protein cofactor increases its affinity for the enzyme in the presence of lipid substrate. In both cases, the apparent dissocn. const. of the lipase-colipase complex is decreased by 1 order of magnitude. The results confirm that the biol. activity of the lipase cofactor is enhanced by specific tryptic cleavage in the N-terminal region of the polypeptide and support the suggestion by B. Borgstroem et al. (1981) that the secreted form of colipase is a precursor.

=>

=> d au ti so 1-32 l3

- L3 ANSWER 1 OF 32 CAPLUS COPYRIGHT 2003 ACS on STN
IN Reszka, Regina; Fichtner, Iduna
TI Orally administered pharmaceutical preparation comprising liposomically encapsulated paclitaxel
SO PCT Int. Appl., 7 pp.
CODEN: PIXXD2
- L3 ANSWER 2 OF 32 MEDLINE on STN DUPLICATE 1
AU Ichihara Hideaki; Nagami Hideaki; Yamamoto Keiichi; Matsumoto Yoko; Ueoka Ryuichi
TI Chemotherapy with hybrid liposomes without any drug in vivo.
SO YAKUGAKU ZASSHI. JOURNAL OF THE PHARMACEUTICAL SOCIETY OF JAPAN, (2003 Jan) 123 (1) 25-34.
Journal code: 0413613. ISSN: 0031-6903.
- L3 ANSWER 3 OF 32 CAPLUS COPYRIGHT 2003 ACS on STN
IN Boni, Lawrence; Wu, Fangjun; Fennimore, Roy; Batenjany, Michael M.
TI Preparation of large liposomes by infusion into an aqueous polymer solution
SO PCT Int. Appl., 34 pp.
CODEN: PIXXD2
- L3 ANSWER 4 OF 32 CAPLUS COPYRIGHT 2003 ACS on STN
IN Cheng, Jui-Ching
TI Compositions and procedures for preventing aggregation of liposomes
SO Ger. Offen., 12 pp.
CODEN: GWXXBX
- L3 ANSWER 5 OF 32 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC. on STN
AU Thierry, Alain R. (1)
TI Liposomal delivery system for biologically active agents.
SO Official Gazette of the United States Patent and Trademark Office Patents, (Aug. 29, 2000) Vol. 1237, No. 5, pp. No Pagination. e-file.
ISSN: 0098-1133.
- L3 ANSWER 6 OF 32 CAPLUS COPYRIGHT 2003 ACS on STN
AU Netti, Paolo A.
TI Movement of macromolecules, particles, and cells in hydrogel.
SO Book of Abstracts, 219th ACS National Meeting, San Francisco, CA, March 26-30, 2000 (2000), POLY-306 Publisher: American Chemical Society, Washington, D. C.
CODEN: 69CLAC
- L3 ANSWER 7 OF 32 CAPLUS COPYRIGHT 2003 ACS on STN
IN Holland, John W.; Madden, Thomas D.; Cullis, Pieter R.
TI Bilayer-stabilizing components and their use in forming programmable fusogenic liposomes
SO PCT Int. Appl., 82 pp.
CODEN: PIXXD2
- L3 ANSWER 8 OF 32 CAPLUS COPYRIGHT 2003 ACS on STN
AU Mizuguchi, H.; Nakanishi, M.; Nakanishi, T.; Nakagawa, T.; Nakagawa, S.; Mayumi, T.
TI Application of fusogenic liposomes containing fragment A of diphtheria toxin to cancer therapy
SO British Journal of Cancer (1996), 73(4), 472-6
CODEN: BJCAAI; ISSN: 0007-0920
- L3 ANSWER 9 OF 32 CAPLUS COPYRIGHT 2003 ACS on STN
AU Makino, Kimiko
TI Stabilization of liposomes for controlled release
SO Fragrance Journal (1996), (4), 85-93

CODEN: FUJAD7; ISSN: 0288-9803

- L3 ANSWER 10 OF 32 CAPLUS COPYRIGHT 2003 ACS on STN
IN Helmus, Michael N.; Tolkoﬀ, M. Joshua; Raleigh, Carol L.
TI Manufacture of medical devices with tissue exposure to release an agent
from reservoir
SO U.S., 16 pp. Cont. of U.S. Ser. No. 525,339, abandoned.
CODEN: USXXAM
- L3 ANSWER 11 OF 32 CAPLUS COPYRIGHT 2003 ACS on STN
AU Gursel, M.; Hasirci, V.
TI Influence of membrane components on the stability and drug release
properties of reverse-phase evaporation vesicles (REVs): light sensitive
all-trans retinal, negatively charged phospholipid dicetylphosphate and
cholesterol
SO Journal of Microencapsulation (1995), 12(6), 661-9
CODEN: JOMIEF; ISSN: 0265-2048
- L3 ANSWER 12 OF 32 CAPLUS COPYRIGHT 2003 ACS on STN
AU Nuernberg, Eberhard; Paspaleeva-Kuehn, Valentina
TI Polyoxyethylated detergents as vesicle components. Part 2
SO Pharmazie in Unserer Zeit (1995), 24(6), 331-8
CODEN: PHUZBI; ISSN: 0048-3664
- L3 ANSWER 13 OF 32 CAPLUS COPYRIGHT 2003 ACS on STN
IN Morikawa, Yasuri; Azuma, Kunio; Aono, Katsutoshi; Sasaki, Atsushi;
Murahashi, Naoichi; Sakagami, Masahiro
TI Preparation of poly(ethylene glycol)-based lipid and glycolipids having
acidic functional groups as micro-particle pharmaceutical carriers
SO Jpn. Kokai Tokkyo Koho, 58 pp.
CODEN: JKXXAF
- L3 ANSWER 14 OF 32 CAPLUS COPYRIGHT 2003 ACS on STN
AU Jaaeskelaeninen, Ilpo; Urtti, Arto
TI Liquid chromatography determination of liposome components using a
light-scattering evaporative detector
SO Journal of Pharmaceutical and Biomedical Analysis (1994), 12(8), 977-82
CODEN: JPBADA; ISSN: 0731-7085
- L3 ANSWER 15 OF 32 CAPLUS COPYRIGHT 2003 ACS on STN
AU Uyama, Ichiro; Kumai, Koichiro; Yasuda, Tatsuji; Tagawa, Toshiaki;
Ishibiki, Kyuya; Kitajima, Masaki; Tadakuma, Takushi
TI Improvement of therapeutic effects by using Fab' fragment in the treatment
of carcinoembryonic antigen-positive human solid tumors with
adriamycin-entrapped immunoliposomes
SO Japanese Journal of Cancer Research (1994), 85(4), 434-40
CODEN: JJCREP; ISSN: 0910-5050
- L3 ANSWER 16 OF 32 CAPLUS COPYRIGHT 2003 ACS on STN
AU Liu, Dexi; Huang, Leaf
TI Interaction of pH-sensitive liposomes with blood components
SO Journal of Liposome Research (1994), 4(1), 121-41
CODEN: JLREE7; ISSN: 0898-2104
- L3 ANSWER 17 OF 32 CAPLUS COPYRIGHT 2003 ACS on STN
IN Bagshawe, Kenneth Dawson
TI Inactivation of cytotoxic drugs in cytotoxic drug therapy, and prodrug
therapy kit
SO PCT Int. Appl., 56 pp.
CODEN: PIXXD2
- L3 ANSWER 18 OF 32 CAPLUS COPYRIGHT 2003 ACS on STN
IN Jerome, Corbiere
TI Pharmaceutical liposomes containing peptides

SO Fr. Demande, 25 pp.
CODEN: FRXXBL

L3 ANSWER 19 OF 32 CAPLUS COPYRIGHT 2003 ACS on STN
IN Mori, Hideto; Nishikawa, Naoyuki
TI Preparation of isoprenoid phospholipids
SO Jpn. Kokai Tokkyo Koho, 12 pp.
CODEN: JKXXAF

L3 ANSWER 20 OF 32 CAPLUS COPYRIGHT 2003 ACS on STN
IN Chang, Tse Wen
TI Conjugates of liposomes or microbeads and antibodies specific for
T-lymphocytes and their use as immunomodulators
SO Can. Pat. Appl., 33 pp.
CODEN: CPXXEB

L3 ANSWER 21 OF 32 CAPLUS COPYRIGHT 2003 ACS on STN
AU Park, Jung Hwan; Lee, Eun Ok; Kim, Jong Duk
TI Preparation and characteristics of phosphatidylcholine liposomes
covalently coupled with immunoglobulin fragments
SO Yakche Hakhoechi (1992), 22(2), 115-24
CODEN: YAHAE; ISSN: 0259-2347

L3 ANSWER 22 OF 32 CAPLUS COPYRIGHT 2003 ACS on STN
IN Sahasrabudde, Chintaman G.
TI Immunoliposomes for transmittal of activating signals to cells in vitro
SO PCT Int. Appl., 17 pp.
CODEN: PIXXD2

L3 ANSWER 23 OF 32 CAPLUS COPYRIGHT 2003 ACS on STN
IN Fukuda, Masahiro; Okano, Tomomichi
TI Sulfofatty acid derivatives for manufacturing pharmaceutical liposomes
SO Jpn. Kokai Tokkyo Koho, 6 pp.
CODEN: JKXXAF

L3 ANSWER 24 OF 32 CAPLUS COPYRIGHT 2003 ACS on STN
IN Seid, Robert C., Jr.; Paradiso, Peter R.; Poolman, Jan T.; Hoogerhout,
Peter; Wiertz, Emmanuel J. H. J.; Van der Ley, Peter; Heckels, John
Edward; Clarke, Ian Nicholas
TI Meningococcal class 1 outer-membrane protein vaccine
SO PCT Int. Appl., 121 pp.
CODEN: PIXXD2

L3 ANSWER 25 OF 32 CAPLUS COPYRIGHT 2003 ACS on STN
IN Hibino, Hidehiko; Iwasaki, Hiroshi; Nakachi, Osamu
TI Preparation of phosphatidylcholines by acylation of glycerophosphocholine
SO Jpn. Kokai Tokkyo Koho, 5 pp.
CODEN: JKXXAF

L3 ANSWER 26 OF 32 CAPLUS COPYRIGHT 2003 ACS on STN
IN Miyaji, Hideki; Hokukoku, Shusaburo; Tomikawa, Munehiro; Hirota, Sadao;
Kikuchi, Hiroshi
TI Preparation of mannobiose derivatives as liposome components
SO Eur. Pat. Appl., 20 pp.
CODEN: EPXXDW

L3 ANSWER 27 OF 32 CAPLUS COPYRIGHT 2003 ACS on STN
AU Peeters, Pierre A. M.; Claessens, Conny A. M.; Eling, Wijnand M. C.;
Crommelin, Daan J. A.
TI Immunospecific targeting of liposomes to erythrocytes
SO Biochemical Pharmacology (1988), 37(11), 2215-22
CODEN: BCPA6; ISSN: 0006-2952

L3 ANSWER 28 OF 32 CAPLUS COPYRIGHT 2003 ACS on STN

AU Ikuta, Kazuyoshi; Ueda, Shigeharu; Uchida, Tsuyoshi; Okada, Yoshio; Kato, Shiro
TI Selective killing of human immunodeficiency virus-infected and -producing cells by liposomes containing diphtheria toxin fragment A
SO Japanese Journal of Cancer Research (1987), 78(11), 1159-63
CODEN: JJCREP; ISSN: 0910-5050

L3 ANSWER 29 OF 32 CAPLUS COPYRIGHT 2003 ACS on STN
IN Sunamoto, Junzo; Sato, Tomonori; Ishii, Nobuko; Shoji, Toshihiko
TI Preparation of liposomes coated with polysaccharides and Fab' fragments of monoclonal antibodies as pharmaceutical carriers
SO Jpn. Kokai Tokkyo Koho, 7 pp.
CODEN: JKXXAF

L3 ANSWER 30 OF 32 CAPLUS COPYRIGHT 2003 ACS on STN
IN Vanlerberghe, Guy; Zysman, Alexandre; Seba, Henri
TI Cyclic alkoxy-substituted hemiacetals as carriers for reactive compounds and as components of liposomes
SO Ger. Offen., 47 pp.
CODEN: GWXXBX

L3 ANSWER 31 OF 32 CAPLUS COPYRIGHT 2003 ACS on STN
AU Bredehorst, Reinhard; Ligler, Frances S.; Kusterbeck, Anne W.; Chang, Eddie L.; Gaber, Bruce P.; Vogel, Carl Wilhelm
TI Effect of covalent attachment of immunoglobulin fragments on liposomal integrity
SO Biochemistry (1986), 25(19), 5693-8
CODEN: BICHAW; ISSN: 0006-2960

L3 ANSWER 32 OF 32 CAPLUS COPYRIGHT 2003 ACS on STN
AU Guo, Luke S. S.; Hamilton, Robert L.; Goerke, Jon; Weinstein, John N.; Havel, Richard J.
TI Interaction of unilamellar liposomes with serum lipoproteins and apolipoproteins
SO Journal of Lipid Research (1980), 21(8), 993-1003
CODEN: JLPRAW; ISSN: 0022-2275

=> d 15 18 bib ab 13

L3 ANSWER 15 OF 32 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1994:548430 CAPLUS
DN 121:148430
TI Improvement of therapeutic effects by using Fab' fragment in the treatment of carcinoembryonic antigen-positive human solid tumors with adriamycin-entrapped immunoliposomes
AU Uyama, Ichiro; Kumai, Koichiro; Yasuda, Tatsuji; Tagawa, Toshiaki; Ishibiki, Kyuya; Kitajima, Masaki; Tadakuma, Takushi
CS Sch. Med., Keio Univ., Tokyo, 160, Japan
SO Japanese Journal of Cancer Research (1994), 85(4), 434-40
CODEN: JJCREP; ISSN: 0910-5050
DT Journal
LA English
AB To improve the therapeutic efficiency of adriamycin entrapped in antibody-conjugated liposomes, a Fab' fragment was used instead of the whole antibody mol. A murine monoclonal antibody, 21B2, against human carcinoembryonic antigen (CEA) was digested with pepsin, and the SH residue of the heavy chain produced by redn. of F(ab')₂ with dithiothreitol was conjugated to liposomes contg. adriamycin. The tissue distribution of adriamycin delivered with these liposomes was studied in BALB/c nu/nu female mice bearing CEA-pos. human gastric cancer strain MKN-45. An increase in delivery of adriamycin to the tumor was obsd. in mice given liposomes with the Fab' fragment as compared to those given liposomes with the whole antibody. However, the preferential distribution

of liposome-borne adriamycin to the reticuloendothelial cells remained the same regardless of the use of Fab' fragment. For investigation of in vivo therapeutic effect, 3 i.v. injections of free adriamycin or of liposome-borne adriamycin (equiv. to 5 mg adriamycin/kg) were given; adriamycin in the Fab' fragment-conjugated liposomes was the most effective in the inhibition of tumor growth. This was confirmed in terms of actual tumor wts. excised and CEA concn. in the blood, as well as by pathol. observations. The advantages of using Fab' fragment instead of whole antibody are discussed.

L3 ANSWER 18 OF 32 CAPLUS COPYRIGHT 2003 ACS on STN

AN 1993:656541 CAPLUS

DN 119:256541

TI Pharmaceuticall liposomes containing peptides

IN Jerome, Corbiere

PA Fr.

SO Fr. Demande, 25 pp.

CODEN: FRXXBL

DT Patent

LA French

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	---	-----	-----	-----
PI	FR 2685868	A1	19930709	FR 1992-18	19920103
	FR 2685868	B1	19950623		
PRAI	FR 1992-18		19920103		

AB Pharmaceutical liposomes contg. peptides for oral or parenteral use are disclosed. Soya phosphatidylcholine, cholesterol, and dicetyl phosphate at a ratio of 7:2:1 were used to prep. liposomes contg. insulin which were filtered over Sepharose 6B and lyophilized.